Thanyanan ReungwetwattanaSylvia JaramilloJulian R. MolinaMayo Medical SchoolMahidol University2018-05-032018-05-032011-01-01Clinical Medicine Insights: Therapeutics. Vol.3, (2011), 125-1351179559X1179559X2-s2.0-79957788903https://repository.li.mahidol.ac.th/handle/20.500.14594/12830Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL. © the author(s), publisher and licensee Libertas Academica Ltd.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.4137/CMT.S3778